Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
ACHFF
Primary Symbol:
V.ARCH
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 28, 2023 8:31pm
Somethings smells here
Yesterday's new release of FDA approval for AKI phase 2 trial should have caught the attention of any interested investors. IMO yesterdays news should have got us back up to $5 with high volume
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 27, 2023 5:32pm
Wild Ride Today
Well I told everybody to buckle up and you sure beeded your seat belt today. $2:14 to $2.38 in the first hour then the shorts stepped back in and quickly knocked in back down to $2.18. We slowly
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Jun 27, 2023 10:17am
RE:News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA
Recent funding contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) announced by the Company in March 2023, will significantly help cover
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Jun 27, 2023 9:38am
News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA
June 27 (Reuters) - Arch Biopartners Inc: * ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA TO PROCEED WITH PHASE II ACUTE KIDNEY INJURY TRIAL * ARCH BIOPARTNERS INC - CS-AKI TRIAL HAS PLANS TO
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Jun 27, 2023 9:11am
RE:New Press Release - Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
"The IND application included preclinical data, Phase I and Phase II clinical data to date, manufacturing processes, and the protocol design for the CS-AKI Phase II trial."
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2023 7:16am
New Press Release - Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation in the lungs, liver and kidneysThere are currently no treatments available...
read article.
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 26, 2023 4:23pm
Nice Push from Anonymous
The last hour of trading lived up to its name of Power Hour. Anonymous was aggressively buying into the close. I think someone knows something here. The tide is turning here folks, the train is
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 24, 2023 12:46pm
Big Week Ahead
Well we are down crunch time here. Management is under the microscope here. They told the markets that phase 2 independent data review would be out before the end of 1st half 2023. So will management
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 21, 2023 2:48pm
Big Buy Orders
I just checked level 2. There are two very large buy orders. 100,000 at $1.88 150,000 at $1.93 Thats a positive sign and obviously someone is very bullish on the stock.
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 20, 2023 2:43pm
Adding Shares
For those who actually read this bullboard or follow this stock, today is a gift with our shorts returning and knocking us back below $2. This low ball share price will not last much longer. We are
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 20, 2023 1:29pm
Shorts are Back
Well we had a brief break yesterday with CIBC and Scotiabank. Neither house was active yesterday selling but CIBC is back today. The fact US markets were closed yesterday might suggest the sellers
...more
(2)
•••
2019champs
X
View Profile
View Bullboard History
Comment by
2019champs
on Jun 19, 2023 10:36pm
RE:House 83 Accumulates Again
Arch is due for news at any point now. Phase 2 Data, and initiation of the AKI trial will be huge milestones. Double digit share price this year isn't far fetched considering where peer groups are
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 19, 2023 7:54pm
House 83 Accumulates Again
Once again house 83 accumulating again today. Look at level 2 150,000 bid at $1.95! Somebody wants to accumulate here. Is news coming? It sure is long overdue and buying with accumulation suggests
...more
(2)
•••
2019champs
X
View Profile
View Bullboard History
Comment by
2019champs
on Jun 17, 2023 11:01am
RE:House 83
Great buying opportunity at these levels! As you stated, this is undervalued compared to peers. Most shareholders are now on another platforn, as pointed out by Antonius. I can share that link via
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment
Xcyte Digital Corp. Releases "Xperience" Subscription Service
Drilling Approval Received for New Mexico Lithium Project